PetMed Express (NASDAQ:PETS) Lowered to "Hold" Rating by StockNews.com

StockNews.com lowered shares of PetMed Express (NASDAQ:PETS - Free Report) from a buy rating to a hold rating in a report published on Tuesday morning.

PetMed Express Stock Down 4.9 %

NASDAQ:PETS traded down $0.22 on Tuesday, reaching $4.25. The stock had a trading volume of 373,859 shares, compared to its average volume of 205,731. The company has a market capitalization of $87.81 million, a P/E ratio of -70.83 and a beta of 0.70. PetMed Express has a 1-year low of $2.90 and a 1-year high of $6.85. The stock has a fifty day moving average price of $5.07 and a 200-day moving average price of $4.33.

PetMed Express (NASDAQ:PETS - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The company reported ($0.03) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.02). PetMed Express had a negative net margin of 0.37% and a negative return on equity of 1.00%. Sell-side analysts predict that PetMed Express will post 0.24 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Leslie C.G. Campbell bought 15,000 shares of the company's stock in a transaction on Wednesday, December 4th. The stock was bought at an average cost of $5.38 per share, with a total value of $80,700.00. Following the completion of the purchase, the director now owns 70,000 shares in the company, valued at approximately $376,600. The trade was a 27.27 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 1.10% of the company's stock.

Institutional Investors Weigh In On PetMed Express

A number of institutional investors and hedge funds have recently modified their holdings of PETS. Metavasi Capital LP raised its stake in shares of PetMed Express by 48.5% during the fourth quarter. Metavasi Capital LP now owns 340,302 shares of the company's stock worth $1,640,000 after buying an additional 111,194 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in shares of PetMed Express by 26.5% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 513,381 shares of the company's stock valued at $2,474,000 after buying an additional 107,614 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of PetMed Express by 355.5% in the fourth quarter. JPMorgan Chase & Co. now owns 106,954 shares of the company's stock valued at $516,000 after buying an additional 83,473 shares during the period. Bleakley Financial Group LLC acquired a new position in shares of PetMed Express in the third quarter valued at approximately $279,000. Finally, Independent Advisor Alliance acquired a new position in shares of PetMed Express in the third quarter valued at approximately $106,000. 73.33% of the stock is owned by institutional investors.

PetMed Express Company Profile

PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.